Financial Performance - The company reported a total revenue of 499,776,892, with a cash dividend of 0.7 yuan per 10 shares to all shareholders[5]. - The company's total revenue for 2020 was CNY 1,481,591,872.64, representing an increase of 11.58% compared to 2019[17]. - The net profit attributable to shareholders for 2020 was CNY 154,550,403.78, up by 11.25% from the previous year[17]. - The net cash flow from operating activities increased by 59.56% to CNY 343,160,357.56[17]. - The basic earnings per share for 2020 were CNY 0.31, reflecting a 10.71% increase from 2019[17]. - The company achieved a total revenue of CNY 1,481.59 million in 2020, representing a year-on-year growth of 11.58%[59]. - The net profit attributable to shareholders reached CNY 154.55 million, an increase of 11.25% compared to the previous year[59]. - The pharmaceutical R&D and production services segment generated revenue of CNY 1,213.50 million, up 10.52% year-on-year, with a significant growth of 15.96% in the last three quarters[61]. - The revenue from the micro-ecological nutrition and medical business reached CNY 27,994.20 million, a year-on-year increase of 20.47%[74]. - The company reported a total revenue of 1.54 billion RMB for the year 2020, reflecting a growth of 8% compared to the previous year[169]. Risk Management - The company faces risks including a decline in service demand, loss of core technology and management personnel, and fluctuations in raw material prices[5]. - The company has a detailed section on risks and countermeasures in its operational discussion, highlighting its proactive approach to risk management[5]. - The company is exposed to raw material price fluctuations, particularly for sucrose and lactose, which could affect production costs and profit margins[127]. - The company confirmed a significant amount of goodwill after acquiring Shanghai Ruizhi, which poses a risk of impairment if future performance does not meet expectations[128]. - The company faces foreign exchange risks primarily related to the US dollar and euro, with most service costs denominated in RMB, potentially impacting profit margins[130]. - The company is at risk of losing key scientific and management personnel, which could significantly impact its operations and service quality[124]. - The company is committed to investing in technology R&D to mitigate the risk of new technology development failures[125]. - The company is closely monitoring regulatory compliance to avoid penalties that could harm its reputation and business operations[126]. - The company acknowledges the impact of unforeseen events, such as natural disasters and public health crises, on its operations and is taking steps to mitigate these risks[136]. Operational Strategy - The company has outlined its future plans and performance forecasts, emphasizing the importance of risk awareness among investors[5]. - The company is exploring market expansion opportunities, particularly in overseas markets, to mitigate risks associated with domestic demand[5]. - The company has established three core business divisions: pharmaceutical research services, micro-ecological nutrition, and micro-ecological medical services, to enhance competitiveness and profitability[129]. - The company aims to enhance its CRO/CDMO service platform and increase market share by leveraging its technological advantages and customer reputation[115]. - The company plans to strengthen its domestic pharmaceutical market expansion and optimize its operational system to align with local market needs[116]. - The company is focused on continuous innovation in technology platforms, including the development of DNA-encoded compound libraries and PROTAC technology platforms[121]. - The company is actively involved in research and development collaborations with various related parties to enhance its product offerings[168]. Compliance and Governance - The board of directors has confirmed the accuracy and completeness of the financial report, ensuring accountability for any misleading statements[4]. - The company emphasizes the importance of compliance with regulatory standards in its operations, particularly in drug development and manufacturing[11]. - The company has established a complete corporate governance structure to ensure independent decision-making[146]. - The company has committed to maintaining the independence of its operations and minimizing related party transactions[145]. - The company has ensured that its financial and operational independence is upheld, with no asset occupation by controlling parties[146]. - The company has established a commitment to avoid any related party transactions that could harm the interests of Quantum High-Tech and its shareholders[147]. - The company has implemented measures to ensure that core management personnel sign confidentiality and non-competition agreements[153]. Investment and Growth - The company has invested significant resources in integrating Shanghai Ruizhi to achieve expected synergies and benefits, while facing risks related to liquidity and unforeseen costs[128]. - The company has established a joint investment fund, ShangPharma Capital LP, with a total scale of 100 million USD, where the company contributed 30 million USD, representing 30% of the fund[171]. - The company aims to enhance its core competitiveness by integrating global pharmaceutical industry resources through its investment in the fund[171]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million yuan set aside for strategic investments[150]. - The company has committed to a lock-up period of 36 months for shares held by key personnel following the IPO[153]. Social Responsibility and Environmental Compliance - The company actively engages in social responsibility initiatives, including participation in global pandemic relief actions[191]. - The company donated over 1 million yuan worth of probiotics to support pandemic relief efforts in Wuhan and other regions[191]. - The company has established a comprehensive quality and environmental health safety (EHS) system in compliance with FDA standards for new drug development[190]. - The company’s waste gas emission concentrations from three outlets were within permissible limits, with the highest concentration being 14.7 mg/m³, well below the maximum allowable of 70 mg/m³[195]. - The company has signed contracts with five licensed hazardous waste disposal units to ensure compliant waste management[196]. Employee and Talent Management - The company has a talent pool of 2,357 employees, with 167 holding doctoral degrees and over 36% possessing a master's degree or higher[54]. - The company intends to attract and manage talent effectively while increasing employee training efforts[116]. - The company has implemented an employee stock option incentive plan, granting 6.73 million stock options to 86 participants[164].

Financial Performance - Operating revenue for the period was CNY 399,134,189.48, representing a year-on-year growth of 17.74%[7] - Net profit attributable to shareholders increased by 32.80% to CNY 42,417,705.30 for the quarter[7] - Basic earnings per share rose by 32.86% to CNY 0.0849[7] - The total revenue for Q3 2020 reached CNY 399.13 million, a year-on-year increase of 17.74%[21] - The net profit attributable to ordinary shareholders for Q3 2020 was CNY 42.42 million, up 32.80% compared to the same period last year[22] - The total operating revenue for the third quarter was CNY 399,134,189.48, an increase of 17.7% compared to CNY 339,010,498.07 in the same period last year[44] - The net profit for the quarter was CNY 42,371,247.95, representing a 34.7% increase from CNY 31,441,311.60 in the previous year[46] - The company achieved an investment income of CNY 6,868,115.24, a significant rise from CNY 422,299.93 in the previous year[45] - The total profit for the year-to-date period was approximately CNY 95.95 million, compared to CNY 88.23 million in the previous year, showing an increase of about 8.9%[53] Cash Flow - Net cash flow from operating activities surged by 150.56% to CNY 94,991,156.69[7] - The net cash flow from operating activities for the first nine months of 2020 was CNY 210.25 million, representing a 155.75% increase from CNY 82.21 million in the previous year[20] - The cash flow from operating activities generated a net cash inflow of CNY 210,247,510.40, compared to CNY 82,209,783.00 in the same quarter last year, marking an increase of about 155.5%[60] - The financing activities generated a net cash inflow of CNY 137,800,028.00, significantly higher than the CNY 19,458,301.81 reported in the previous year[61] - The total operating cash inflow for the quarter was CNY 1,097,787,620.12, compared to CNY 947,565,207.83 in the previous year, indicating a growth of about 15.8%[60] Assets and Liabilities - Total assets increased by 12.11% to CNY 4,223,948,068.93 compared to the end of the previous year[7] - The total assets as of September 30, 2020, reached ¥4.22 billion, up from ¥3.77 billion at the end of 2019, indicating an increase of about 12%[39] - The total liabilities increased to ¥1.86 billion as of September 30, 2020, from ¥1.46 billion at the end of 2019, marking an increase of about 27.3%[38] - The company's equity increased to CNY 2,118,531,423.71, up from CNY 2,111,586,050.28, reflecting a growth of 0.3%[42] - Total liabilities reached CNY 1,464,373,815.50, with current liabilities at CNY 789,243,355.34 and non-current liabilities at CNY 675,130,460.16[69] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,215[11] - The top ten shareholders held a combined 66.29% of the company's shares, with Yunnan Babon Health Industry Co., Ltd. holding the largest share at 16.05%[11] Research and Development - The research and development expenses were CNY 23,945,558.61, which is a significant increase of 91.1% compared to CNY 12,540,040.38 in the same quarter last year[45] - The company is constructing a one-stop R&D and production service platform for innovative biopharmaceuticals in Qidong, Jiangsu, and a global innovative drug cGMP Phase II production base in Fengxian, Shanghai[28] Government Support - The company received government subsidies amounting to CNY 5,138,230.37 during the reporting period[8] - The deferred income increased by 85.18% to CNY 9.66 million, primarily due to an increase in government subsidies during the reporting period[16] Risks and Commitments - The company faced a risk of not meeting the 2020 performance commitment for Shanghai Ruizhi, with a promised net profit of no less than CNY 239 million[26] - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[29] - The company has not engaged in any illegal external guarantees during the reporting period[30] Other Financial Metrics - The company reported a decrease of 9.95% in net profit attributable to shareholders after deducting non-recurring gains and losses, totaling CNY 36,265,037.50[7] - The weighted average return on net assets was 1.83%, an increase of 0.39 percentage points compared to the previous year[7] - The company reported an investment income of approximately CNY 1.79 million for the third quarter of 2020, up from CNY 1.61 million in the previous year[49] - The total comprehensive income for the year-to-date period was approximately CNY 73.51 million, down from CNY 83.88 million in the previous year, reflecting a decrease of about 12.5%[54]

Financial Performance - The company's operating revenue for the current reporting period is ¥670,228,150.02, representing an increase of 8.96% compared to the same period last year[20]. - The net profit attributable to shareholders for the current period is ¥40,888,811.58, showing a decrease of 16.94% year-over-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is ¥30,887,949.98, down 31.92% from the previous year[20]. - The net cash flow from operating activities increased significantly by 160.18%, reaching ¥115,256,353.71[20]. - The total assets at the end of the reporting period are ¥3,956,362,905.28, which is a 5.01% increase from the end of the previous year[20]. - The revenue from pharmaceutical research services and production outsourcing reached ¥522,630,740.19, with a year-on-year increase of 1.69%[86]. - Revenue from micro-ecological nutritional preparations was ¥144,721,272.72, showing a significant year-on-year increase of 50.54%[86]. - Investment income amounted to ¥7,816,070.65, contributing 17.56% to total profit, with sustainable earnings from equity method investments[88]. - The gross profit margin for the first half of 2020 was 29.60%, down from 36.35% in the same period last year[69]. - The company’s operating income was 670.23 million yuan, an 8.96% increase year-on-year, driven by sales growth in the micro-ecological and pharmaceutical R&D services[83]. Risks and Challenges - The company faces risks including a decline in demand for pharmaceutical R&D services, intensified competition, talent loss, and goodwill impairment[5]. - The company is exposed to intensified competition in the global pharmaceutical R&D services market, which may adversely affect its performance[114]. - The company is at risk of losing key clients, which could lead to a significant decline in revenue[116]. - The company faces risks related to regulatory compliance and the potential inability to obtain necessary licenses, which could significantly impact its operations[121]. - The company acknowledges the impact of unforeseen events, such as natural disasters and public health crises like COVID-19, on its operational capabilities[126]. - The company faces foreign exchange risks primarily related to USD and EUR, with a potential impact on profit margins if the RMB appreciates against the USD[121]. Operational Strategies - The report includes a detailed analysis of the company's operational risks and corresponding mitigation strategies[5]. - The company plans to continuously invest in personnel and capital for technology R&D innovation to enhance its core capabilities[117]. - The company is actively integrating Shanghai Ruizhi to enhance competitiveness and profitability, establishing a comprehensive financial reporting and responsibility system[120]. - The company is exploring various measures to mitigate raw material price volatility, including sugar futures hedging and improving production processes[118]. - The company has established a risk management strategy to address potential government regulatory risks in various countries[117]. Market Position and Growth - The company has established itself as the third-largest drug discovery and preclinical research outsourcing service provider in China, and the second-largest in biopharmaceutical R&D outsourcing services[49]. - The global biopharmaceutical R&D services market is projected to grow from $4.8 billion in 2012 to $20 billion by 2021, indicating significant growth potential for biopharmaceutical R&D service providers[55]. - The CDMO/CMO market is projected to grow as small pharmaceutical companies, which accounted for 76.8% of the total in 2019, are expected to rise to 79.1% by 2023, driving innovation[41]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies[146]. - Strategic partnerships and collaborations are being explored to strengthen market presence and operational efficiency[146]. Environmental and Compliance - The company has established a comprehensive environmental protection management system, ensuring compliance with environmental laws and regulations[180]. - The company has implemented self-monitoring programs for environmental protection, including annual air monitoring and quarterly wastewater and noise monitoring[179]. - The company emphasizes green chemistry initiatives, focusing on reducing hazardous chemical usage and improving synthesis efficiency[182]. - The company has made significant investments in environmental protection technologies, enhancing its management and technical capabilities[180]. - The company has established a hazardous waste management system to ensure proper disposal and prevent environmental pollution[183]. Shareholder Information - The company has a total of 499,776,892 shares, with 80.75% being unrestricted shares[191]. - The largest shareholder, Yunnan Babon Health Industry Co., Ltd., holds 16.05% of the shares, totaling 80,199,000 shares, which are pledged[193]. - The second-largest shareholder, Hangzhou Ciyuan Liangjia Investment Management Partnership, holds 11.82% of the shares, totaling 59,094,000 shares[193]. - The total number of common shareholders at the end of the reporting period was 14,560[193]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[195]. Legal and Regulatory Matters - A subsidiary, Kaihui Pharmaceutical, was fined RMB 800,000 for environmental pollution, with an appeal currently in process[135]. - The company believes the lawsuit will not impact its current or future profits[136]. - The total amount involved in the lawsuit against Kaihui Pharmaceutical is RMB 5.8246 million[137]. - The company has not initiated any poverty alleviation programs in the reporting period[186]. - The company has no significant litigation matters other than the aforementioned lawsuit[138].

Financial Performance - Total revenue for Q1 2020 was ¥278,744,900.86, a decrease of 6.31% compared to ¥297,504,646.00 in the same period last year[8] - Net profit attributable to shareholders was -¥14,153,944.58, representing a decline of 155.41% from ¥25,544,886.50 in the previous year[8] - Basic and diluted earnings per share were both -¥0.0283, down 155.38% from ¥0.0511 in the same period last year[8] - The company reported a total comprehensive income of CNY -11,573,086.66 for the first quarter of 2020, compared to CNY 22,786,717.41 in the previous year[55] - The net profit for the first quarter of 2020 was a loss of CNY 14,251,522.60, compared to a profit of CNY 25,051,189.23 in the same period last year, indicating a significant decline[55] - The operating profit for the first quarter of 2020 was a loss of CNY 16,643,679.99, down from a profit of CNY 29,563,065.54 in the previous year[54] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 65.15% to ¥17,227,621.05 from ¥49,439,947.78 year-on-year[8] - The company's cash and cash equivalents decreased by 38.08% to CNY 124.48 million, mainly due to reduced cash inflow during the pandemic[16] - The total cash and cash equivalents at the end of the period were 123,005,493.36 CNY, down from 187,271,038.41 CNY in the previous period[63] - The company reported a net increase in cash and cash equivalents of -76,569,086.18 CNY, compared to -2,060,998.76 CNY in the previous period[63] - Cash inflows from operating activities totaled CNY 265,171,648.29, down from CNY 312,485,717.42 in the previous year, a decrease of approximately 15.1%[60] Assets and Liabilities - Total assets increased by 1.22% to ¥3,813,797,034.47 from ¥3,767,716,601.98 at the end of the previous year[8] - Total liabilities amounted to CNY 1,531,062,461.98, compared to CNY 1,464,373,815.50 in the previous period, reflecting an increase of 4.5%[47] - The company's total equity attributable to shareholders was CNY 2,280,413,255.64, slightly down from CNY 2,291,888,764.28[48] - Non-current assets totaled CNY 3,021,852,554.43, an increase from CNY 2,967,529,527.86 year-over-year[46] Revenue Breakdown - Revenue from pharmaceutical R&D services and production outsourcing was CNY 222.81 million, down 8.53% year-on-year due to slower project execution[18] - The micro-ecological nutrition and medical business achieved revenue of CNY 60.54 million, an increase of 14.06% year-on-year, reflecting heightened market awareness of health management[18] Strategic Developments - The company established a subsidiary in Hong Kong to further implement its international strategy in micro-ecology[20] - The company has established new strategic planning and organizational adjustments to enhance synergy with its subsidiary Shanghai Ruizhi, focusing on biopharmaceutical R&D services and creating a global health industry innovation service platform[23] - Following a major asset restructuring, the company has expanded its business to include biopharmaceutical and chemical drug development, aiming to effectively integrate resources across different business units to achieve greater synergy[24] Risks and Challenges - Rising costs, particularly in human resources and raw materials, pose a challenge; the company is implementing measures to attract and retain talent while controlling expenses[29] - Fluctuations in raw material prices, especially for sugar and lactose, could significantly impact product costs and profit margins; the company is exploring hedging strategies to manage these risks[30] - The competitive landscape in the CRO and CMO industry is evolving, with increasing competition potentially impacting the company's market share and profitability[26] Compliance and Legal Matters - Kaihui Pharmaceutical was fined RMB 800,000 for environmental pollution, with the company appealing the decision[34] - The lawsuit's outcome is not expected to impact the company's current or future profits[35] - As of the report date, Kaihui Pharmaceutical's operations remain normal, and the involved personnel do not include current or former executives of the company[36] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,116[12] - The largest shareholder, Yunnan Babon Health Industry Co., Ltd., held 16.05% of shares, amounting to 80,199,000 shares[12] Operational Adjustments - The company has fully resumed operations and is actively pursuing its annual operational plan despite the challenges posed by the pandemic[19] - The company is in the process of transferring business contracts to ensure operational independence[38]

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the year 2019, representing a year-on-year growth of 20%[13] - The net profit for 2019 was 300 million RMB, an increase of 15% compared to the previous year[13] - The company's operating revenue for 2019 was CNY 1,327,826,062.35, representing a 33.19% increase compared to CNY 996,915,339.60 in 2018[19] - The net profit attributable to shareholders for 2019 was CNY 138,922,368.49, a decrease of 13.75% from CNY 161,077,249.83 in 2018[19] - The net profit after deducting non-recurring gains and losses was CNY 118,950,350.00, down 20.53% from CNY 149,687,465.71 in 2018[19] - The company's cash flow from operating activities was CNY 215,069,587.63, a decline of 11.56% compared to CNY 243,186,611.69 in 2018[19] - The total assets at the end of 2019 were CNY 3,767,716,601.98, an increase of 12.55% from CNY 3,347,701,009.32 at the end of 2018[19] - The basic earnings per share for 2019 were CNY 0.28, down 20.00% from CNY 0.35 in 2018[19] - The weighted average return on net assets was 6.20%, a decrease of 4.55% from 10.75% in 2018[19] - The company reported a net profit of -1,156.93 million RMB from the quantum magnetic system industry fund, primarily due to interest on raised funds and unrealized investment returns[132] Market Expansion and Strategy - User data indicated a 25% increase in active users, reaching 2 million by the end of 2019[13] - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2022[13] - The company aims for a revenue growth target of 25% for 2020, driven by new product launches and market expansion efforts[13] - The company plans to enhance its position as a leader in the global health industry through a multi-division operational strategy[27] - The company is actively pursuing international market expansion and increasing its customer base to mitigate risks associated with fluctuations in downstream customer demand[165] Research and Development - The company has allocated 100 million RMB for R&D in 2020, focusing on innovative biopharmaceutical technologies[13] - New product development includes a line of probiotics expected to launch in Q3 2020, projected to generate 200 million RMB in revenue[13] - The company has established a comprehensive R&D system covering various aspects of prebiotic research, with ongoing collaborations with renowned medical institutions to facilitate technology transfer[65] - The company has advanced capabilities in drug development, having helped clients advance over 80 monoclonal antibody drugs through various milestone stages, and has cumulatively advanced over 200 drug targets[59] - The company is committed to optimizing production processes and accelerating the development of new products, including oligosaccharides and special medical foods[155] Quality Assurance and Compliance - The company has established a comprehensive quality assurance system, including ISO9001 and ISO22000 certifications, ensuring high standards in food safety and quality[48] - The company has implemented strict quality control measures across all production stages to ensure product safety and compliance with regulatory standards[171] - The company’s international leading standard laboratories and production bases are designed to meet cGMP specifications for new drug production[39] Financial Management and Investments - The company does not plan to distribute cash dividends for the fiscal year 2019, opting to reinvest profits into growth initiatives[6] - The company increased its long-term equity investments by 85.18%, primarily due to investments in ShangPharma Capital LP[51] - The company has established a joint venture and an industrial merger fund, with a total investment of 90 million RMB in the quantum magnetic system industry fund, representing 33.21% of the fund's share[133] - The company has committed to maintaining independence in operations, personnel, finance, and business, ensuring no interference from controlling parties[187] Risks and Challenges - Risks identified include market competition and potential impacts from the COVID-19 pandemic, with mitigation strategies outlined in the report[5] - The company is facing increased competition in the CRO and CMO sectors, which may affect its market share and profitability, but it is positioned to benefit from industry growth trends[163] - The company has noted fluctuations in raw material costs, particularly for sugar and lactose, which could impact profit margins if prices rise significantly[168] Product and Service Development - The company operates a comprehensive CRO and CMO service model, covering both biological and chemical drugs[28] - The CRO business covers various drug types, including chemical and biological drugs, offering comprehensive services from discovery to clinical trials, which enhances client communication efficiency and R&D effectiveness[56] - The company has launched five innovative drugs in the U.S. over the past two years, enhancing its R&D capabilities[105] Corporate Governance - The company has established a commitment to reduce and regulate related party transactions, ensuring fair pricing and compliance with legal procedures[187] - The company guarantees the independence of its financial department and accounting system, ensuring no shared bank accounts with controlling parties[187] - The company has pledged to disclose any unavoidable related party transactions in accordance with legal requirements[198]

Financial Performance - Operating revenue decreased by 5.91% to CNY 339,010,498.07 for the current period, but increased by 53.72% to CNY 954,145,831.72 year-to-date[7] - Net profit attributable to shareholders decreased by 45.04% to CNY 31,940,729.91 for the current period, and decreased by 27.76% to CNY 81,171,456.40 year-to-date[7] - Basic earnings per share decreased by 45.06% to CNY 0.0639 for the current period, and decreased by 35.25% to CNY 0.1624 year-to-date[7] - The weighted average return on equity decreased by 1.31% to 1.44% for the current period, and decreased by 5.16% to 3.66% year-to-date[7] - The company's total revenue for Q3 2019 was CNY 339.01 million, a year-on-year decrease of 5.91%[19] - The net profit attributable to ordinary shareholders for Q3 2019 was CNY 31.94 million, a decrease of 45.04% year-on-year, primarily due to increased investment in the Jiangsu Qidong innovative biopharmaceutical R&D platform and higher financial expenses from acquisition loans[20] - The comprehensive income total for Q3 2019 was CNY 35,086,515.89, down 44.5% from CNY 62,859,407.83 in the same quarter last year[39] - The total comprehensive income attributable to the parent company was CNY 35,585,934.20, down from CNY 62,962,035.07 in the previous period, representing a decrease of approximately 43.5%[40] Assets and Liabilities - Total assets increased by 7.82% to CNY 3,609,563,241.24 compared to the end of the previous year[7] - The company's total liabilities reached CNY 1,359,659,757.90, compared to CNY 1,143,195,367.00 at the end of 2018, marking an increase of about 18.9%[30][31] - The company's equity attributable to shareholders increased to CNY 2,237,019,891.90 from CNY 2,190,031,453.40, reflecting a growth of approximately 2.1%[31] - The company's current assets totaled CNY 800,078,419.51, compared to CNY 735,316,120.59 at the end of 2018, reflecting a growth of approximately 8.8%[28][29] - Accounts receivable increased to CNY 440,008,423.78 from CNY 335,589,920.50, representing a rise of about 31.1% year-over-year[28][29] - Inventory levels rose significantly to CNY 79,693,999.20, up from CNY 49,891,639.97, indicating a growth of approximately 59.8%[28][29] - Current liabilities rose to CNY 134,472,447.99, an increase of 52.0% compared to CNY 88,470,155.36 in the previous year[35] Cash Flow and Investments - The net cash flow from operating activities decreased by 46.26% to CNY 82,209,783.00 year-to-date[7] - The cash flow from operating activities generated a net amount of CNY 82,209,783.00, down 46.0% from CNY 152,970,509.37 in the same period last year[53] - Investment activities resulted in a net cash outflow of CNY 131,763,321.06, compared to a net outflow of CNY 903,908,978.07 in the previous year[53] - The company incurred financial expenses of CNY 28,551,119.67, significantly higher than CNY 8,954,222.06 in the same quarter last year[49] - The company received CNY 39,414,715.48 in tax refunds, compared to CNY 5,116,432.74 in the previous year[51] Research and Development - The company's R&D expenses for the first nine months of 2019 were CNY 38.08 million, an increase of 151.15% year-on-year, reflecting ongoing increases in overall R&D investment[17] - Research and development expenses increased to CNY 12,540,040.38, up 51.8% from CNY 8,258,398.78 year-on-year[38] - Research and development expenses were CNY 10,682,314.33, a slight increase from CNY 10,244,947.72 year-over-year[49] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,833[11] - The largest shareholder, Yunnan Babon Health Industry Co., Ltd., holds 16.05% of the shares, totaling 80,199,000 shares[11] - No repurchase transactions were conducted by the top 10 shareholders during the reporting period[12] Other Financial Information - The company received government subsidies amounting to CNY 5,906,992.72 during the reporting period[8] - The company reported no violations regarding external guarantees during the reporting period[23] - There were no overdue commitments from controlling shareholders or related parties during the reporting period[24] - The company has not disclosed any cash dividend policies during the reporting period[23] - The company did not apply new financial instrument standards or new revenue standards for the year 2019[58] - The Q3 2019 report was not audited[58]

Financial Performance - Total revenue for the reporting period reached ¥615,135,333.65, representing a 136.22% increase compared to ¥260,413,310.34 in the same period last year[17]. - Net profit attributable to shareholders decreased by 9.27% to ¥49,230,726.48 from ¥54,257,849.79 year-on-year[17]. - The net cash flow from operating activities fell by 33.16% to ¥44,298,591.75, down from ¥66,279,839.88 in the previous year[17]. - The basic earnings per share decreased by 23.08% to ¥0.10 from ¥0.13 year-on-year[17]. - The weighted average return on net assets dropped to 2.23% from 6.49% in the previous year, a decline of 4.26%[17]. - Revenue from pharmaceutical R&D services and production outsourcing reached CNY 514.29 million, a year-on-year increase of 7.79%[62]. - Revenue from micro-ecological nutrition and medical services was CNY 101.25 million, a decline of 37.21% compared to the previous year[62]. - The net profit for the micro-ecological nutrition and medical business was CNY 1.10 million, a significant decline of 96.90% year-on-year[63]. - The company’s total revenue for the first half of 2019 was 8,387.4 million CNY[137]. - The company reported a total rental income of 46,904.27 million CNY from leasing properties, with a loss of 1,253.14 million CNY during the reporting period[146]. Business Operations - The company's CRO and CMO business accounted for 83.60% of total revenue, with biological business revenue making up 57.96% of this segment[25]. - International business contributed 72% to the revenue from pharmaceutical research services, while domestic business accounted for 28%[34]. - The company has established a supplier management system to enhance cost control and improve procurement efficiency[33]. - The company has served over 1,600 clients globally, including 18 of the top 20 multinational pharmaceutical companies since 2015[34]. - The company has established long-term stable partnerships with top 20 multinational pharmaceutical companies, which is the foundation for stable and scalable CRO performance[35]. - The company has developed over 200 drug targets in new drug research, positioning itself among the top three in the domestic preclinical CRO market[37]. - The biological drug R&D department has helped advance over 70 monoclonal antibody drugs through various milestone stages[38]. - The company has established a tumor cell bank with over 800 tumor cell lines, including nearly 50 unique primary tumor cell lines[39]. - The pharmacokinetics research department has developed over 5,000 in vitro activity screening methods and over 300 target confirmation methods[40]. - The company has advanced capabilities in drug development, providing comprehensive services across various drug types, including chemical and biological drugs[50]. Market Position and Strategy - The company was recognized as one of the "Top 10 Leading CMOs" by Pharma Tech Outlook in 2019, reflecting its strong industry position[61]. - The company plans to accelerate the expansion of its product matrix and focus on new application areas to drive future growth[61]. - The company aims to enhance its competitive edge and profitability through the integration of Shanghai Ruizhi's capabilities and resources[106]. - The company is focusing on expanding its international market presence and enhancing sales of end products to mitigate risks associated with demand fluctuations[111]. - Quantum High-Tech aims to leverage its technological advantages in the prebiotic industry and increase R&D investment to provide comprehensive health management solutions for chronic diseases[110]. Financial Health and Investments - Total assets increased by 2.93% to ¥3,445,928,472.93 from ¥3,347,701,009.32 at the end of the previous year[17]. - The company’s long-term equity investments increased by 32.79% compared to the beginning of the year, primarily due to investments in the pharmaceutical innovation industry investment fund and Guangdong Quantum High-Tech Health Management Technology Co., Ltd.[47]. - The company’s cash and cash equivalents decreased by 49.64% compared to the beginning of the year, mainly due to investments in construction projects and cash dividend distribution during the period[47]. - The company’s inventory increased by 38.02% compared to the beginning of the year, attributed to increased production projects and procurement of semi-finished products[47]. - The company has invested RMB 255.494 million in bank wealth management products, with an outstanding balance of RMB 70.994 million[96]. - The company has established a joint venture, Tianjin Quantum Magnetic Asset Management Co., Ltd., and a partnership fund, with a total investment of RMB 90 million[104]. Risks and Challenges - The company emphasizes the importance of risk awareness among investors regarding potential risks such as business integration, goodwill impairment, market competition, and product quality[4]. - The company faces risks related to goodwill impairment following the acquisition of Shanghai Ruizhi, which could negatively impact its financial performance[107]. - Rising costs and expenses, particularly in human resources, pose a risk to the company's profitability as it expands its operations[112]. - The procurement prices of key raw materials, such as white sugar and lactose, are subject to significant volatility, which can affect product margins[113]. - The fluctuation in demand from downstream customers in the dairy and health products sectors significantly impacted the company's revenue and profits during the reporting period[111]. Environmental and Social Responsibility - The company has established an environmental risk assessment report and is currently in the review phase for its emergency response plan[154]. - The company conducts annual monitoring for various pollutants, including acetonitrile and isopropanol, with specific limits set for each[155]. - The company has implemented a comprehensive environmental monitoring scheme to ensure compliance with local regulations[157]. - The company emphasizes green chemistry initiatives, focusing on reducing the use of hazardous chemicals and improving synthesis efficiency[160]. - The company has established a hazardous waste management system to ensure proper classification and disposal of hazardous waste by qualified third parties[161]. Shareholder and Corporate Governance - The company has committed to a voluntary lock-up period of 36 months for key personnel, during which they will not transfer or manage shares acquired before the IPO[121]. - The company has granted 6.73 million stock options to 86 incentive targets as part of its stock option incentive plan initiated in 2017[130]. - The company has fulfilled all commitments made by its shareholders regarding share transfer limitations[122]. - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[173].

Financial Performance - Total revenue for Q1 2019 reached ¥297,504,646, representing a 276.79% increase compared to ¥78,956,898 in the same period last year[8] - Net profit attributable to shareholders was ¥25,544,886.50, up 134.79% from ¥10,879,751.77 year-on-year[8] - Net profit excluding non-recurring items was ¥23,892,125.92, reflecting a 175.95% increase from ¥8,658,220.39 in the previous year[8] - Basic earnings per share rose to ¥0.0511, an increase of 98.06% from ¥0.0258[8] - The company reported a total profit of ¥29,490,508.70 for Q1 2019, compared to ¥13,086,352.74 in the previous year, representing an increase of 125.0%[55] - The comprehensive income for Q1 2019 was ¥22,786,717.41, compared to ¥10,199,599.67 in Q1 2018, reflecting an increase of 123.0%[55] Cash Flow - Net cash flow from operating activities was ¥49,439,947.78, a significant increase of 396.99% compared to ¥9,947,824.79 in the same period last year[8] - Cash flow from operating activities generated a net amount of 49,439,947.78, an increase of 396.06% compared to 9,947,824.79 in the previous period[60] - Cash flow from investment activities resulted in a net outflow of -33,210,227.32, improving from -193,311,643.55 in the previous period[60] - Cash flow from financing activities showed a net outflow of -17,777,478.10, compared to a net inflow of 10,750,000.00 in the previous period[61] - The total cash and cash equivalents at the end of the period were 187,271,038.41, a decrease from 118,883,262.28 in the previous period[61] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,396,670,529.92, a 1.46% increase from ¥3,347,701,009.32 at the end of the previous year[8] - The company's total assets as of the end of Q1 2019 amounted to ¥2,762,340,924.20, slightly down from ¥2,773,777,079.57 at the end of the previous quarter[52] - The company's total liabilities were CNY 1,168,578,690.20, compared to CNY 1,143,195,367.00 at the end of 2018, marking an increase of about 2.2%[47] - The company's current assets decreased to CNY 720,388,102.21 from CNY 735,316,120.59, reflecting a decline of approximately 2.4%[45] - Accounts receivable increased to CNY 355,031,580.98 from CNY 337,579,456.88, representing a growth of about 5.1%[45] Operational Highlights - The company achieved total operating revenue of CNY 297.50 million in Q1 2019, a year-on-year increase of 276.79%, primarily due to the consolidation of Shanghai Ruizhi's financial results[19] - Operating cash flow net amount reached CNY 49.44 million, a significant increase of 396.99% year-on-year, mainly due to the consolidation of Shanghai Ruizhi[21] - Research and development expenses increased by 224.77% to CNY 10.43 million, reflecting the impact of the newly consolidated Shanghai Ruizhi[19] - The company reported a 355.17% increase in operating costs, amounting to CNY 185.73 million, primarily due to the consolidation of Shanghai Ruizhi[19] Strategic Initiatives - The company plans to enhance its core micro-ecological nutrition products and expand into new application areas to meet market demand[25] - The company is focusing on integrating Shanghai Ruizhi into its operations to leverage synergies and improve competitiveness[27] - The company is actively developing its tumor product marketing model and establishing a service system for gut microbiota intervention[26] - The company has extended its business into pharmaceutical research and outsourcing services after a major asset restructuring, focusing on integrating various business units to achieve synergistic effects[28] Risks and Challenges - The company anticipates risks related to the integration and collaboration with Shanghai Ruizhi, which may impact future development[26] - The acquisition of Shanghai Ruizhi has resulted in significant goodwill, which poses a risk of impairment if future performance does not meet expectations; however, the CRO and CMO sectors are expected to grow, benefiting the company[29] - The CRO and CMO industries are experiencing rapid growth, but increased competition may impact the company's market share and profitability; the company aims to leverage its leading position in the industry[30] - Rising costs, particularly in human resources, pose a challenge as the company scales; it plans to implement long-term incentive mechanisms to attract and retain talent while controlling expenses[33] - Fluctuations in raw material prices, especially for sugar and lactose, could significantly impact product costs and margins; the company is exploring hedging strategies and improving production efficiency to mitigate these risks[34] - The company faces potential legal risks related to its subsidiary, Kaihui Pharmaceutical, which is under investigation for environmental pollution; this could lead to penalties affecting operations[37] Compliance and Standards - The company did not undergo an audit for the first quarter report[67] - The company implemented new financial instrument standards starting January 1, 2019, with no impact on the opening balances[65]

Financial Performance - The company's operating revenue for 2018 was CNY 996,915,339.60, representing a 262.05% increase compared to CNY 275,353,625.05 in 2017[18]. - The net profit attributable to shareholders for 2018 was CNY 161,077,249.83, an increase of 178.63% from CNY 57,809,509.47 in 2017[18]. - The net cash flow from operating activities reached CNY 243,186,611.69, up 283.37% from CNY 63,433,286.02 in 2017[18]. - The total assets at the end of 2018 amounted to CNY 3,347,701,009.32, a 220.91% increase from CNY 1,043,177,285.54 in 2017[18]. - The basic earnings per share for 2018 was CNY 0.35, a 150.00% increase from CNY 0.14 in 2017[18]. - The weighted average return on equity for 2018 was 10.75%, up from 7.33% in 2017[18]. - The net profit after deducting non-recurring gains and losses for 2018 was CNY 149,687,465.71, a 207.32% increase from CNY 48,707,018.48 in 2017[18]. - The company reported a total of CNY 11,389,784.12 in non-recurring gains for 2018, compared to CNY 9,102,490.99 in 2017[23]. - The company achieved a gross profit margin improved to 50.64%, up from 45.62% year-on-year[68]. - The company reported a net profit attributable to ordinary shareholders of CNY 161.08 million, an increase of 178.63% year-on-year[65]. Dividend Distribution - The company plans to distribute a cash dividend of 0.70 CNY per 10 shares to all shareholders, based on a total of 499,776,892 shares[4]. - The company achieved a 100% cash dividend payout ratio from its distributable profits, reflecting its commitment to returning value to shareholders[188]. - In 2018, the company proposed a cash dividend of RMB 0.70 per 10 shares, totaling RMB 34,984,382.44, which represents 21.72% of the net profit attributable to shareholders[190]. - The cash dividends for 2017 and 2016 were RMB 16,884,000.00 (29.21% of net profit) and RMB 21,105,000.00 (32.48% of net profit) respectively[190]. - The total cash dividends distributed over the last three years amounted to RMB 72,973,382.44, reflecting a consistent dividend policy[190]. Acquisitions and Business Expansion - The company acquired 90% of Shanghai Ruizhi, a leading domestic CRO, through a share issuance and cash payment, completing the registration on May 31, 2018[27]. - The company plans to continue expanding its market presence and investing in new technologies following the acquisition of Shanghai Ruizhi[27]. - The acquisition of Shanghai Ruizhi has expanded the company's business into pharmaceutical research and production outsourcing, significantly enhancing its service capabilities[101]. - The company is integrating Shanghai Ruizhi's capabilities to promote balanced development across its business units, particularly in biopharmaceutical R&D services[172]. - The company plans to enhance its production capacity for oligosaccharides to meet growing market demand and expand into new application areas[168]. Market Position and Client Base - The pharmaceutical R&D services and outsourcing production business accounted for 69.70% of the company's total revenue during the reporting period[29]. - The company serves over 1,000 clients globally, with 72% of its revenue coming from international business and only 28% from domestic sources[32]. - The company has maintained long-term stable partnerships with 18 of the top 20 global pharmaceutical companies, ensuring a diverse and growing client base[33]. - The company has a strong market position in the prebiotic industry, with proprietary technology in enzyme engineering and strain selection[44]. - The customer base for micro-ecological nutrition has grown by 23.60% year-on-year, totaling 749 clients, primarily in the domestic market[43]. Research and Development - The company has established a comprehensive antibody drug development platform, integrating various technologies to enhance its R&D capabilities[38]. - The company has accumulated over 5,000 in vitro activity screening methods and over 500 cell activity screening methods, enhancing its pharmacokinetics research capabilities[40]. - The company has a high-level talent team with 179 PhDs, and 42% of employees hold a master's degree or higher, supporting its R&D capabilities[53]. - The company is focused on expanding its product categories in prebiotics to meet consumer health needs and is conducting research on human milk oligosaccharides[88]. - The company has established a micro-ecological medical research center and is actively developing products in chronic disease management, including diabetes and cancer[91]. Financial Health and Investments - The company reported a 390.85% increase in intangible assets, attributed to the acquisition of Shanghai Ruizhi's land use rights and patent technology[47]. - The company has seen a 163.91% increase in long-term equity investments compared to the beginning of the year, primarily due to reclassification of financial assets[47]. - The company has a total investment for the reporting period reached ¥2,144,000,000.00, a significant increase of 1,011.11% compared to ¥192,960,300.00 in the previous year[124]. - Cash inflow from financing activities increased by 242.52% to ¥709,800,000.00, primarily due to funds borrowed for the acquisition of Shanghai Ruizhi[114]. - The company has committed to ensuring the independence of its operations, including financial and personnel independence, as part of its corporate governance[191]. Risks and Challenges - The company acknowledges various risks including market competition risk and product quality risk, which may impact future performance[4]. - The company faces risks related to goodwill impairment due to the acquisition of Shanghai Ruizhi, which could negatively impact future performance if expected results are not achieved[173]. - The company is addressing market competition risks by leveraging its position as a leading one-stop pharmaceutical R&D service provider to benefit from industry growth trends[174]. - The company has a risk of being penalized due to environmental pollution allegations, but it is currently operating normally and has engaged legal counsel for the ongoing case[182]. - The company recognizes the need for consumer education on prebiotics to expand market demand, despite potential fluctuations in the health food market[160]. Corporate Governance - The company has established a governance structure that allows for independent decision-making by its board and shareholders[192]. - The actual controller and related parties have strictly adhered to commitments regarding the reduction and regulation of related party transactions[191]. - Quantum High-Tech has committed to ensuring financial independence by establishing an independent financial department and accounting system[193]. - The company has pledged to avoid any related party transactions that are not conducted at fair market prices[193]. - The company has committed to providing accurate and complete information regarding its transactions to protect shareholder interests[194].

2018 年 10 月 1 量子高科（中国）生物股份有限公司 2018 年第三季度报告全文 量子高科（中国）生物股份有限公司 2018 年第三季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪经、主管会计工作负责人辜团力及会计机构负责人(会计主 管人员)王凤容声明：保证季度报告中财务报表的真实、准确、完整。 2 量子高科（中国）生物股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 量子高科（中国）生物股份有限公司 2018 年第三季度报告全文 第一节 重要提示 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,372,716,412.05 | 1,043,177,285.54 | | 223.31% | | 归属于上市公司股东的 ...